NVO and NOVOB:DC Related Headlines
Go Back- Morgan Stanley Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Equalweight
- Goldman Sachs Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK270 at Barclays
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK309 at Citi
- Kepler Cheuvreux Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
- Deutsche Bank Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
- JPMorgan Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK340 at Barclays
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK360 at Berenberg
- Jefferies Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK400 at Deutsche Bank
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK332 at UBS
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK340 at Citi
- Citi Starts Novo Nordisk (NOVOB:DC) (NVO) at Neutral
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK436 at Goldman Sachs
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK415 at Berenberg
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK390 at UBS
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK360 at Barclays
- Kepler Cheuvreux Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK430 at Kepler Cheuvreux
- UBS Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Berenberg Reiterates Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK295 at UBS
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK270 at Morgan Stanley
- HSBC Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK400 at Berenberg
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK475 at Deutsche Bank
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK315 at UBS
- Jefferies Assumes Novo Nordisk (NOVOB:DC) (NVO) at Underperform
- Berenberg Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Goldman Sachs Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- UBS Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Morgan Stanley Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Underweight
- Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- UBS Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Berenberg Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
- Rothschild Redburn Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Buy
- Bernstein SocGen Group Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Outperform
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK510 at Kepler Cheuvreux
- BNP Paribas Exane Upgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
- Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK355 at HSBC
- BofA Securities Reiterates Neutral Rating on Novo Nordisk (NOVOB:DC) (NVO)
- UBS Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
- Barclays on GLP-1s: 'we caution that price erosion across GLP-1 class could come faster and more deeply than we expected'
- HSBC Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Hold
- BofA Securities Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Neutral
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK500 at JPMorgan
- Barclays Downgrades Novo Nordisk (NOVOB:DC) (NVO) to Equalweight
- Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK600 at UBS
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK745 at Goldman Sachs
- UBS Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- JPMorgan Reiterates Overweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
- UBS Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- UBS Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Novo Nordisk (NOVOB:DC) (NVO) PT Lowered to DKK650 at JPMorgan

